FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023
Source: iQoncept / Shutterstock
Homology Medicines (NASDAQ:FIXX) just reported results for the fourth quarter of 2023.
- Homology Medicines reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -30 cents.
- The company did not report any revenue for the quarter.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/fixx-stock-earnings-homology-medicines-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC